Business · 29/09/2020Updated: 10/17/2026 · 1 min read
FDA Renews Cardiovascular and Renal Drugs Advisory Committee for 2 Years
Summary
The FDA has renewed the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on August 27, 2024.